Generic Name and Formulations:
Dexamethasone 0.7mg in the Novadur delivery system; intravitreal implant; preservative-free.
Indications for OZURDEX:
Macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Non-infectious uveitis affecting the posterior segment of the eye. Diabetic macular edema.
For ophthalmic intravitreal injection only. One implant in each affected eye(s).
Ocular or periocular infections. Glaucoma (cup to disc ratio >0.8). Torn or ruptured posterior lens capsule.
Monitor for intravitreal injection-related effects (eg, endophthalmitis, eye inflammation, increased intraocular pressure, retinal detachments) following the injection. Risk of potential steroid-related effects (eg, posterior subcapsular cataracts, glaucoma, secondary ocular infections). History of ocular herpes simplex: not recommended. Risk of implant migration to anterior chamber if posterior lens capsule is not intact. Pregnancy. Nursing mothers.
Increased intraocular pressure, conjunctival hemorrhage, eye pain, conjunctival hyperemia, ocular hypertension, cataracts.
Single-use intravitreal implant—1 (w. applicator)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- A Simplified Dose Schedule of Cetuximab as a Maintenance Therapy in Head and Neck Cancer May Reduce Drug Toxicities
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline